摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-naphthalen-1-yl-3H-[1,3,4]thiadiazole-2-thione | 28813-62-9

中文名称
——
中文别名
——
英文名称
5-naphthalen-1-yl-3H-[1,3,4]thiadiazole-2-thione
英文别名
2α-Naphthyl-1,3,4-thiadiazoline-5-thione;5-naphthalen-1-yl-3H-1,3,4-thiadiazole-2-thione
5-naphthalen-1-yl-3<i>H</i>-[1,3,4]thiadiazole-2-thione化学式
CAS
28813-62-9
化学式
C12H8N2S2
mdl
——
分子量
244.341
InChiKey
ATKAZYRTMSWANJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    81.8
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] INHIBITORS OF HUMAN 15-LIPOXYGENASE-1<br/>[FR] INHIBITEURS DE LA 15-LIPOXYGÉNASE-1 HUMAINE
    申请人:US HEALTH
    公开号:WO2011028651A1
    公开(公告)日:2011-03-10
    Disclosed are inhibitors of human 15 lipoxygenase 1, for example, of formula (I), wherein R1, R2, R3, R4, X, Y, and Z are as defined herein, that are useful in treating a 15-lipoxygenase mediated disease or disorder, e.g., prostate cancer. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating prostate cancer in a mammal.
    本文披露了人类15-脂氧合酶1的抑制剂,例如式(I)中的抑制剂,其中R1、R2、R3、R4、X、Y和Z如本文所定义,这些抑制剂对治疗15-脂氧合酶介导的疾病或紊乱,例如前列腺癌,具有有用性。还披露了一种包含药用载体和本发明中至少一种化合物的组合物,以及一种治疗哺乳动物前列腺癌的方法。
  • Discovery of Potent and Selective Inhibitors of Human Reticulocyte 15-Lipoxygenase-1
    作者:Ganesha Rai、Victor Kenyon、Ajit Jadhav、Lena Schultz、Michelle Armstrong、J. Brian Jameson、Eric Hoobler、William Leister、Anton Simeonov、Theodore R. Holman、David J. Maloney
    DOI:10.1021/jm1008852
    日期:2010.10.28
    There are a variety of lipoxygenases in the human body (hLO), each having a distinct role in cellular biology. Human reticulocyte 15-lipoxygenase-1 (15-hLO-1), which catalyzes the dioxygenation of 1,4-cis,cis-pentadiene-containing polyunsaturated fatty acids, is implicated in a number of diseases including cancer, atherosclerosis, and neurodegenerative conditions. Despite the potential therapeutic relevance of this target, few inhibitors have been reported that are both potent and selective. To this end, we have employed a quantitative high-throughput (qHTS) screen against similar to 74000 small molecules in search of reticulocyte 15-hLO-1 selective inhibitors. This screen led to the discovery of a novel chemotype for 15-hLO-1 inhibition, which displays nM potency and is > 7500-fold selective against the related isozymes, 5-hLO, platelet 12-hLO, epithelial 15-hLO-2, ovine cyclooxygenase-1, and human cyclooxygenase-2. In addition, kinetic experiments were performed which indicate that this class of inhibitor is tight binding, reversible, and appears not to reduce the active-site ferric ion.
  • US6080772A
    申请人:——
    公开号:US6080772A
    公开(公告)日:2000-06-27
  • Kubota,S. et al., Chemical and pharmaceutical bulletin, 1970, vol. 18, # 8, p. 1696 - 1698
    作者:Kubota,S. et al.
    DOI:——
    日期:——
  • Efficient copper-catalyzed C–S cross-coupling of heterocyclic thiols with aryl iodides
    作者:Liang-Feng Niu、Yan Cai、Chao Liang、Xin-Ping Hui、Peng-Fei Xu
    DOI:10.1016/j.tet.2011.02.064
    日期:2011.4
    A copper-catalyzed cross-coupling of heterocyclic thiols with aryl iodides is reported. The reaction was carried out in the presence of CuI (5 mol %), 1,10-phenanthroline (10 mol %) and K2CO3 (1.3 equiv) in DMF at 120 °C. A variety of heterocyclic sulfides were prepared in high selectivities and yields.
    据报道,铜催化的杂环硫醇与芳基碘化物的交叉偶联。反应在120℃下在CuI(5mol%),1,10-菲咯啉(10mol%)和K 2 CO 3(1.3当量)的存在下在DMF中进行。以高选择性和高产率制备了各种杂环硫化物。
查看更多